Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | RB1 | P06400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24994309 | 0.92 | OPRM1 (0.47) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL658055 | 0.77 | GRIN2B (0.62) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL16761666 | 0.77 | OPRM1 (0.56) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| Hydrochloric Acid SCHEMBL5238529 | 0.76 | GRIN2B (0.61) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL663239 | 0.75 | GRIN2B (0.74) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL21744422 | 0.74 | OPRM1 (0.60) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL21744620 | 0.74 | OPRM1 (0.65) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL19853699 | 0.73 | GRIN2B (0.54) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| Hydrochloric Acid SCHEMBL31629842 | 0.73 | OPRM1 (0.66) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| Methylene Chloride SCHEMBL27437439 | 0.73 | GRIN2B (0.57) | OPRM1OPRL1GRIN2BACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | OPRM1 4678/4885OPRL1 4863/4885GRIN2B 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.